Global Inactivated Vaccine Market Research Report 2022(Status and Outlook)

June 2022 | 110 pages | ID: GD868770F756EN
Bosson Research

Abstracts

Report Overview

The Global Inactivated Vaccine Market Size was estimated at USD 6001.19 million in 2021 and is projected to reach USD 7549.37 million by 2028, exhibiting a CAGR of 3.33% during the forecast period.

Bosson Research’s latest report provides a deep insight into the global Inactivated Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Inactivated Vaccine Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Inactivated Vaccine market in any manner.

Global Inactivated Vaccine Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

• Astellas Pharma (Japan)
• CSL Limited (Australia)
• Emergent BioSolutions (U.S.)
• GlaxoSmithKline (U.K.)
• Johnson and Johnson (U.S.)
• MedImmune (U.S.)
• Merck and Co (U.S.)
• Pfizer (U.S.)
• Sanofi Pasteur (France)
• Serum Institute of India Pvt (India)

Market Segmentation (by Type)

• Children
• Adult

Market Segmentation (by Application)

• Hospital
• Medical Center

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Inactivated Vaccine Market
• Overview of the regional outlook of the Inactivated Vaccine Market:

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Inactivated Vaccine Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Inactivated Vaccine
1.2 Key Market Segments
  1.2.1 Inactivated Vaccine Segment by Type
  1.2.2 Inactivated Vaccine Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 INACTIVATED VACCINE MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Inactivated Vaccine Market Size (M USD) Estimates and Forecasts (2017-2028)
  2.1.2 Global Inactivated Vaccine Sales Estimates and Forecasts (2017-2028)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 INACTIVATED VACCINE MARKET COMPETITIVE LANDSCAPE

3.1 Global Inactivated Vaccine Sales by Manufacturers (2017-2022)
3.2 Global Inactivated Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.3 Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Inactivated Vaccine Average Price by Manufacturers (2017-2022)
3.5 Manufacturers Inactivated Vaccine Sales Sites, Area Served, Product Type
3.6 Inactivated Vaccine Market Competitive Situation and Trends
  3.6.1 Inactivated Vaccine Market Concentration Rate
  3.6.2 Global 5 and 10 Largest Inactivated Vaccine Players Market Share by Revenue
  3.6.3 Mergers & Acquisitions, Expansion

4 INACTIVATED VACCINE INDUSTRY CHAIN ANALYSIS

4.1 Inactivated Vaccine Industry Chain Analysis
4.2 Market Overview and Market Concentration Analysis of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF INACTIVATED VACCINE MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
  5.5.1 New Product Developments
  5.5.2 Mergers & Acquisitions
  5.5.3 Expansions
  5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies

6 INACTIVATED VACCINE MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Inactivated Vaccine Sales Market Share by Type (2017-2022)
6.3 Global Inactivated Vaccine Market Size Market Share by Type (2017-2022)
6.4 Global Inactivated Vaccine Price by Type (2017-2022)

7 INACTIVATED VACCINE MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Inactivated Vaccine Market Sales by Application (2017-2022)
7.3 Global Inactivated Vaccine Market Size (M USD) by Application (2017-2022)
7.4 Global Inactivated Vaccine Sales Growth Rate by Application (2017-2022)

8 INACTIVATED VACCINE MARKET SEGMENTATION BY REGION

8.1 Global Inactivated Vaccine Sales by Region
  8.1.1 Global Inactivated Vaccine Sales by Region
  8.1.2 Global Inactivated Vaccine Sales Market Share by Region
8.2 North America
  8.2.1 North America Inactivated Vaccine Sales by Country
  8.2.2 U.S.
  8.2.3 Canada
  8.2.4 Mexico
8.3 Europe
  8.3.1 Europe Inactivated Vaccine Sales by Country
  8.3.2 Germany
  8.3.3 France
  8.3.4 U.K.
  8.3.5 Italy
  8.3.6 Russia
8.4 Asia Pacific
  8.4.1 Asia Pacific Inactivated Vaccine Sales by Region
  8.4.2 China
  8.4.3 Japan
  8.4.4 South Korea
  8.4.5 India
  8.4.6 Southeast Asia
8.5 South America
  8.5.1 South America Inactivated Vaccine Sales by Country
  8.5.2 Brazil
  8.5.3 Argentina
  8.5.4 Columbia
8.6 Middle East and Africa
  8.6.1 Middle East and Africa Inactivated Vaccine Sales by Region
  8.6.2 Saudi Arabia
  8.6.3 UAE
  8.6.4 Egypt
  8.6.5 Nigeria
  8.6.6 South Africa

9 KEY COMPANIES PROFILED

9.1 Astellas Pharma (Japan)
  9.1.1 Astellas Pharma (Japan) Inactivated Vaccine Basic Information
  9.1.2 Astellas Pharma (Japan) Inactivated Vaccine Product Overview
  9.1.3 Astellas Pharma (Japan) Inactivated Vaccine Product Market Performance
  9.1.4 Astellas Pharma (Japan) Business Overview
  9.1.5 Astellas Pharma (Japan) Inactivated Vaccine SWOT Analysis
  9.1.6 Astellas Pharma (Japan) Recent Developments
9.2 CSL Limited (Australia)
  9.2.1 CSL Limited (Australia) Inactivated Vaccine Basic Information
  9.2.2 CSL Limited (Australia) Inactivated Vaccine Product Overview
  9.2.3 CSL Limited (Australia) Inactivated Vaccine Product Market Performance
  9.2.4 CSL Limited (Australia) Business Overview
  9.2.5 CSL Limited (Australia) Inactivated Vaccine SWOT Analysis
  9.2.6 CSL Limited (Australia) Recent Developments
9.3 Emergent BioSolutions (U.S.)
  9.3.1 Emergent BioSolutions (U.S.) Inactivated Vaccine Basic Information
  9.3.2 Emergent BioSolutions (U.S.) Inactivated Vaccine Product Overview
  9.3.3 Emergent BioSolutions (U.S.) Inactivated Vaccine Product Market Performance
  9.3.4 Emergent BioSolutions (U.S.) Business Overview
  9.3.5 Emergent BioSolutions (U.S.) Inactivated Vaccine SWOT Analysis
  9.3.6 Emergent BioSolutions (U.S.) Recent Developments
9.4 GlaxoSmithKline (U.K.)
  9.4.1 GlaxoSmithKline (U.K.) Inactivated Vaccine Basic Information
  9.4.2 GlaxoSmithKline (U.K.) Inactivated Vaccine Product Overview
  9.4.3 GlaxoSmithKline (U.K.) Inactivated Vaccine Product Market Performance
  9.4.4 GlaxoSmithKline (U.K.) Business Overview
  9.4.5 GlaxoSmithKline (U.K.) Inactivated Vaccine SWOT Analysis
  9.4.6 GlaxoSmithKline (U.K.) Recent Developments
9.5 Johnson and Johnson (U.S.)
  9.5.1 Johnson and Johnson (U.S.) Inactivated Vaccine Basic Information
  9.5.2 Johnson and Johnson (U.S.) Inactivated Vaccine Product Overview
  9.5.3 Johnson and Johnson (U.S.) Inactivated Vaccine Product Market Performance
  9.5.4 Johnson and Johnson (U.S.) Business Overview
  9.5.5 Johnson and Johnson (U.S.) Inactivated Vaccine SWOT Analysis
  9.5.6 Johnson and Johnson (U.S.) Recent Developments
9.6 MedImmune (U.S.)
  9.6.1 MedImmune (U.S.) Inactivated Vaccine Basic Information
  9.6.2 MedImmune (U.S.) Inactivated Vaccine Product Overview
  9.6.3 MedImmune (U.S.) Inactivated Vaccine Product Market Performance
  9.6.4 MedImmune (U.S.) Business Overview
  9.6.5 MedImmune (U.S.) Recent Developments
9.7 Merck and Co (U.S.)
  9.7.1 Merck and Co (U.S.) Inactivated Vaccine Basic Information
  9.7.2 Merck and Co (U.S.) Inactivated Vaccine Product Overview
  9.7.3 Merck and Co (U.S.) Inactivated Vaccine Product Market Performance
  9.7.4 Merck and Co (U.S.) Business Overview
  9.7.5 Merck and Co (U.S.) Recent Developments
9.8 Pfizer (U.S.)
  9.8.1 Pfizer (U.S.) Inactivated Vaccine Basic Information
  9.8.2 Pfizer (U.S.) Inactivated Vaccine Product Overview
  9.8.3 Pfizer (U.S.) Inactivated Vaccine Product Market Performance
  9.8.4 Pfizer (U.S.) Business Overview
  9.8.5 Pfizer (U.S.) Recent Developments
9.9 Sanofi Pasteur (France)
  9.9.1 Sanofi Pasteur (France) Inactivated Vaccine Basic Information
  9.9.2 Sanofi Pasteur (France) Inactivated Vaccine Product Overview
  9.9.3 Sanofi Pasteur (France) Inactivated Vaccine Product Market Performance
  9.9.4 Sanofi Pasteur (France) Business Overview
  9.9.5 Sanofi Pasteur (France) Recent Developments
9.10 Serum Institute of India Pvt (India)
  9.10.1 Serum Institute of India Pvt (India) Inactivated Vaccine Basic Information
  9.10.2 Serum Institute of India Pvt (India) Inactivated Vaccine Product Overview
  9.10.3 Serum Institute of India Pvt (India) Inactivated Vaccine Product Market Performance
  9.10.4 Serum Institute of India Pvt (India) Business Overview
  9.10.5 Serum Institute of India Pvt (India) Recent Developments

10 INACTIVATED VACCINE MARKET FORECAST BY REGION

10.1 Global Inactivated Vaccine Market Size Forecast
10.2 Global Inactivated Vaccine Market Forecast by Region
  10.2.1 North America Market Size Forecast by Country
  10.2.2 Europe Inactivated Vaccine Market Size Forecast by Country
  10.2.3 Asia Pacific Inactivated Vaccine Market Size Forecast by Region
  10.2.4 South America Inactivated Vaccine Market Size Forecast by Country
  10.2.5 Middle East and Africa Forecasted Consumption of Inactivated Vaccine by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2022-2028)

11.1 Global Inactivated Vaccine Market Forecast by Type (2022-2028)
  11.1.1 Global Forecasted Sales of Inactivated Vaccine by Type (2022-2028)
  11.1.2 Global Inactivated Vaccine Market Size Forecast by Type (2022-2028)
  11.1.3 Global Forecasted Price of Inactivated Vaccine by Type (2022-2028)
11.2 Global Inactivated Vaccine Market Forecast by Application (2022-2028)
  11.2.1 Global Inactivated Vaccine Sales (K Units) Forecast by Application
  11.2.2 Global Inactivated Vaccine Market Size (M USD) Forecast by Application (2022-2028)

12 CONCLUSION AND KEY FINDINGSLIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Inactivated Vaccine Market Size (M USD) Comparison by Region (M USD)
Table 5. Global Inactivated Vaccine Sales (K Units) by Manufacturers (2017-2022)
Table 6. Global Inactivated Vaccine Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Inactivated Vaccine Revenue (M USD) by Manufacturers (2017-2022)
Table 8. Global Inactivated Vaccine Revenue Share by Manufacturers (2017-2022)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine as of 2021)
Table 10. Global Market Inactivated Vaccine Average Price (USD/Unit) of Key Manufacturers (2017-2022)
Table 11. Manufacturers Inactivated Vaccine Sales Sites and Area Served
Table 12. Manufacturers Inactivated Vaccine Product Type
Table 13. Global Inactivated Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Inactivated Vaccine
Table 16. Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Inactivated Vaccine Market Challenges
Table 22. Market Restraints
Table 23. Global Inactivated Vaccine Sales by Type (K Units)
Table 24. Global Inactivated Vaccine Market Size by Type (M USD)
Table 25. Global Inactivated Vaccine Sales (K Units) by Type (2017-2022)
Table 26. Global Inactivated Vaccine Sales Market Share by Type (2017-2022)
Table 27. Global Inactivated Vaccine Market Size (M USD) by Type (2017-2022)
Table 28. Global Inactivated Vaccine Market Size Share by Type (2017-2022)
Table 29. Global Inactivated Vaccine Price (USD/Unit) by Type (2017-2022)
Table 30. Global Inactivated Vaccine Sales (K Units) by Application
Table 31. Global Inactivated Vaccine Market Size by Application
Table 32. Global Inactivated Vaccine Sales by Application (2017-2022) & (K Units)
Table 33. Global Inactivated Vaccine Sales Market Share by Application (2017-2022)
Table 34. Global Inactivated Vaccine Sales by Application (2017-2022) & (M USD)
Table 35. Global Inactivated Vaccine Market Share by Application (2017-2022)
Table 36. Global Inactivated Vaccine Sales Growth Rate by Application (2017-2022)
Table 37. Global Inactivated Vaccine Sales by Region (2017-2022) & (K Units)
Table 38. Global Inactivated Vaccine Sales Market Share by Region (2017-2022)
Table 39. North America Inactivated Vaccine Sales by Country (2017-2022) & (K Units)
Table 40. Europe Inactivated Vaccine Sales by Country (2017-2022) & (K Units)
Table 41. Asia Pacific Inactivated Vaccine Sales by Region (2017-2022) & (K Units)
Table 42. South America Inactivated Vaccine Sales by Country (2017-2022) & (K Units)
Table 43. Middle East and Africa Inactivated Vaccine Sales by Region (2017-2022) & (K Units)
Table 44. Astellas Pharma (Japan) Inactivated Vaccine Basic Information
Table 45. Astellas Pharma (Japan) Inactivated Vaccine Product Overview
Table 46. Astellas Pharma (Japan) Inactivated Vaccine Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 47. Astellas Pharma (Japan) Business Overview
Table 48. Astellas Pharma (Japan) Inactivated Vaccine SWOT Analysis
Table 49. Astellas Pharma (Japan) Recent Developments
Table 50. CSL Limited (Australia) Inactivated Vaccine Basic Information
Table 51. CSL Limited (Australia) Inactivated Vaccine Product Overview
Table 52. CSL Limited (Australia) Inactivated Vaccine Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 53. CSL Limited (Australia) Business Overview
Table 54. CSL Limited (Australia) Inactivated Vaccine SWOT Analysis
Table 55. CSL Limited (Australia) Recent Developments
Table 56. Emergent BioSolutions (U.S.) Inactivated Vaccine Basic Information
Table 57. Emergent BioSolutions (U.S.) Inactivated Vaccine Product Overview
Table 58. Emergent BioSolutions (U.S.) Inactivated Vaccine Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 59. Emergent BioSolutions (U.S.) Business Overview
Table 60. Emergent BioSolutions (U.S.) Inactivated Vaccine SWOT Analysis
Table 61. Emergent BioSolutions (U.S.) Recent Developments
Table 62. GlaxoSmithKline (U.K.) Inactivated Vaccine Basic Information
Table 63. GlaxoSmithKline (U.K.) Inactivated Vaccine Product Overview
Table 64. GlaxoSmithKline (U.K.) Inactivated Vaccine Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 65. GlaxoSmithKline (U.K.) Business Overview
Table 66. GlaxoSmithKline (U.K.) Inactivated Vaccine SWOT Analysis
Table 67. GlaxoSmithKline (U.K.) Recent Developments
Table 68. Johnson and Johnson (U.S.) Inactivated Vaccine Basic Information
Table 69. Johnson and Johnson (U.S.) Inactivated Vaccine Product Overview
Table 70. Johnson and Johnson (U.S.) Inactivated Vaccine Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 71. Johnson and Johnson (U.S.) Business Overview
Table 72. Johnson and Johnson (U.S.) Inactivated Vaccine SWOT Analysis
Table 73. Johnson and Johnson (U.S.) Recent Developments
Table 74. MedImmune (U.S.) Inactivated Vaccine Basic Information
Table 75. MedImmune (U.S.) Inactivated Vaccine Product Overview
Table 76. MedImmune (U.S.) Inactivated Vaccine Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 77. MedImmune (U.S.) Business Overview
Table 78. MedImmune (U.S.) Recent Developments
Table 79. Merck and Co (U.S.) Inactivated Vaccine Basic Information
Table 80. Merck and Co (U.S.) Inactivated Vaccine Product Overview
Table 81. Merck and Co (U.S.) Inactivated Vaccine Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 82. Merck and Co (U.S.) Business Overview
Table 83. Merck and Co (U.S.) Recent Developments
Table 84. Pfizer (U.S.) Inactivated Vaccine Basic Information
Table 85. Pfizer (U.S.) Inactivated Vaccine Product Overview
Table 86. Pfizer (U.S.) Inactivated Vaccine Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 87. Pfizer (U.S.) Business Overview
Table 88. Pfizer (U.S.) Recent Developments
Table 89. Sanofi Pasteur (France) Inactivated Vaccine Basic Information
Table 90. Sanofi Pasteur (France) Inactivated Vaccine Product Overview
Table 91. Sanofi Pasteur (France) Inactivated Vaccine Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 92. Sanofi Pasteur (France) Business Overview
Table 93. Sanofi Pasteur (France) Recent Developments
Table 94. Serum Institute of India Pvt (India) Inactivated Vaccine Basic Information
Table 95. Serum Institute of India Pvt (India) Inactivated Vaccine Product Overview
Table 96. Serum Institute of India Pvt (India) Inactivated Vaccine Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 97. Serum Institute of India Pvt (India) Business Overview
Table 98. Serum Institute of India Pvt (India) Recent Developments
Table 99. Global Inactivated Vaccine Sales Forecast by Region (K Units)
Table 100. Global Inactivated Vaccine Market Size Forecast by Region (M USD)
Table 101. North America Inactivated Vaccine Sales Forecast by Country (2022-2028) & (K Units)
Table 102. North America Inactivated Vaccine Market Size Forecast by Country (2022-2028) & (M USD)
Table 103. Europe Inactivated Vaccine Sales Forecast by Country (2022-2028) & (K Units)
Table 104. Europe Inactivated Vaccine Market Size Forecast by Country (2022-2028) & (M USD)
Table 105. Asia Pacific Inactivated Vaccine Sales Forecast by Region (2022-2028) & (K Units)
Table 106. Asia Pacific Inactivated Vaccine Market Size Forecast by Region (2022-2028) & (M USD)
Table 107. South America Inactivated Vaccine Sales Forecast by Country (2022-2028) & (K Units)
Table 108. South America Inactivated Vaccine Market Size Forecast by Country (2022-2028) & (M USD)
Table 109. Middle East and Africa Inactivated Vaccine Consumption Forecast by Country (2022-2028) & (Units)
Table 110. Middle East and Africa Inactivated Vaccine Market Size Forecast by Country (2022-2028) & (M USD)
Table 111. Global Inactivated Vaccine Sales Forecast by Type (2022-2028) & (K Units)
Table 112. Global Inactivated Vaccine Market Size Forecast by Type (2022-2028) & (M USD)
Table 113. Global Inactivated Vaccine Price Forecast by Type (2022-2028) & (USD/Unit)
Table 114. Global Inactivated Vaccine Sales (K Units) Forecast by Application (2022-2028)
Table 115. Global Inactivated Vaccine Market Size Forecast by Application (2022-2028) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Inactivated Vaccine
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Inactivated Vaccine Market Size (M USD), 2017-2028
Figure 5. Global Inactivated Vaccine Market Size (M USD) (2017-2028)
Figure 6. Global Inactivated Vaccine Sales (K Units) & (2017-2028)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Inactivated Vaccine Market Size (M USD) by Country (M USD)
Figure 11. Inactivated Vaccine Sales Share by Manufacturers in 2020
Figure 12. Global Inactivated Vaccine Revenue Share by Manufacturers in 2020
Figure 13. Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 14. Global Market Inactivated Vaccine Average Price (USD/Unit) of Key Manufacturers in 2020
Figure 15. The Global 5 and 10 Largest Players: Market Share by Inactivated Vaccine Revenue in 2021
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Inactivated Vaccine Market Share by Type
Figure 18. Sales Market Share of Inactivated Vaccine by Type (2017-2022)
Figure 19. Sales Market Share of Inactivated Vaccine by Type in 2021
Figure 20. Market Size Share of Inactivated Vaccine by Type (2017-2022)
Figure 21. Market Size Market Share of Inactivated Vaccine by Type in 2020
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Inactivated Vaccine Market Share by Application
Figure 24. Global Inactivated Vaccine Sales Market Share by Application (2017-2022)
Figure 25. Global Inactivated Vaccine Sales Market Share by Application in 2021
Figure 26. Global Inactivated Vaccine Market Share by Application (2017-2022)
Figure 27. Global Inactivated Vaccine Market Share by Application in 2020
Figure 28. Global Inactivated Vaccine Sales Growth Rate by Application (2017-2022)
Figure 29. Global Inactivated Vaccine Sales Market Share by Region (2017-2022)
Figure 30. North America Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 31. North America Inactivated Vaccine Sales Market Share by Country in 2020
Figure 32. U.S. Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 33. Canada Inactivated Vaccine Sales (K Units) and Growth Rate (2017-2022)
Figure 34. Mexico Inactivated Vaccine Sales (Units) and Growth Rate (2017-2022)
Figure 35. Europe Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 36. Europe Inactivated Vaccine Sales Market Share by Country in 2020
Figure 37. Germany Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 38. France Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 39. U.K. Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 40. Italy Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 41. Russia Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 42. Asia Pacific Inactivated Vaccine Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Inactivated Vaccine Sales Market Share by Region in 2020
Figure 44. China Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 45. Japan Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 46. South Korea Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 47. India Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 48. Southeast Asia Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 49. South America Inactivated Vaccine Sales and Growth Rate (K Units)
Figure 50. South America Inactivated Vaccine Sales Market Share by Country in 2020
Figure 51. Brazil Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 52. Argentina Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 53. Columbia Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 54. Middle East and Africa Inactivated Vaccine Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Inactivated Vaccine Sales Market Share by Region in 2020
Figure 56. Saudi Arabia Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 57. UAE Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 58. Egypt Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 59. Nigeria Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 60. South Africa Inactivated Vaccine Sales and Growth Rate (2017-2022) & (K Units)
Figure 61. Global Inactivated Vaccine Sales Forecast by Volume (2017-2028) & (K Units)
Figure 62. Global Inactivated Vaccine Market Size Forecast by Value (2017-2028) & (M USD)
Figure 63. Global Inactivated Vaccine Sales Market Share Forecast by Type (2022-2028)
Figure 64. Global Inactivated Vaccine Market Share Forecast by Type (2022-2028)
Figure 65. Global Inactivated Vaccine Sales Forecast by Application (2022-2028)
Figure 66. Global Inactivated Vaccine Market Share Forecast by Application (2022-2028)